February 4th, 2012
(APDN.OB) Applied DNA Sciences Moves Forward Within Government, Banking, And Insurance Industries
Posted on 16. Mar, 2011 by PublicWire
(PublicWire.com News Release) Applied DNA Sciences, Inc. (OTCQB:APDN), announces new customers and inquiries within the governments and the banking and insurance industries.
Applied DNA provides DNA markers to protect cash and valuables in transit (CViT), to protectbrand owners, and to secure legitimate supply chains against the diversion to gray markets and against the infiltration of counterfeit products. The company’s approach to each vertical market has been to sell its unique, uncopyable DNA tags to suppliers whose components enter at the bottom or through multiple points within a supply chain, and then license the platform to “pain
points” that experience the most liability.
Licensing Model Similar to Software Industry
For example, within the cash transportation industry, APDN sells its DNA markers to the security ink users, ATM cassette manufacturers, and cash box manufacturers, who supply their DNA-enhanced products to security companies and ATM owners. However, the security value in the event of theft can only be realized if the risk-owner has licensed the platform from APDN.
License Unlocks the DNA Sequence Key
“Our model is similar to that employed by the software industry,” said Dr. James Hayward, CEO of APDN. “We ensure widespread deployment of our DNA marks within an industry, in the same manner as software developers distribute software via laptops and device manufacturers. Our licensees can only realize the value of the DNA markers, just as software must be licensed to enjoy its value.” He continued: “Our DNA sequence content is only available to our licensees.
We maintain control of our sequences, and only we can authenticate the cash stolen and provide forensic support in an act perpetrated against a risk-owner, which is initially the cash-intransit transporter, but ultimately includes the financial institution and their insurer.”
APDN now has a proven track record within the CViT industry. With over 22 convictions to its credit, APDN has a 100% conviction record for captured criminals who have stolen cash from its security licensees within the UK. The result, the deterrence provided by APDN, yielded a significant drop in attacks and eliminated cash losses more than one hundred times the cost of annual licensing.
Proven Return on Investment
This proven ROI has brought APDN customers higher up the risk chain. “Banks, insurers and governments are now recognizing the deterrence that can only be provided by DNA markers,” said Dr. Hayward. “We have received initial orders from governments and insurers, and we are fielding inquiries from banks internationally. The increased demand contributed to the closing of the best quarter in our company’s history, announced in SEC filings that describe our first FY11 quarter, ending December 2010.”
About APDN
APDN sells patented DNA security solutions that provide anti-counterfeit protection, as well as protecting brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used for product authentication in a unique manner that essentially cannot be copied. When used in conjunction with other law enforcement technologies, SigNature DNA can provide a forensic chain of evidence that has been used successfully in more than 22 convictions. To learn more, go to www.adnas.com where APDN routinely posts all press releases.
The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to ur short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K, filed on December 15, 2010 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.
SOURCE Applied DNA Sciences, Inc.
INVESTOR CONTACT: Debbie Bailey, 631-444-8090, fax: 631-444-8848
MEDIA CONTACT: Janice Meraglia, 631-444-6293, fax: 631-444-8848
FCMN Contact: info@adnas.com
Web site: http://www.adnas.com
Trading Symbols
Applied DNA Sciences trades Over The Counter As APDN (OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN)
About PublicWire.com
PublicWire.com is a Small Cap Financial Press Release Company that uses a variety of cutting edge methods to syndicate your Small Cap Press Release to various news and information outlets. Our press releases have consitantly placed the Small Cap Companies we work with on the first result page of major search engines such as Google, Bing, and Yahoo. We work exclusively with Pinksheet and Over The Counter (PK and OTCBB) Companies to ensure maximum exposure for their Press Releases.
To maximize your OTCBB / Pinksheet / Small Cap Company Press Release, call us directly at 407-218-7446.
OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN
The symbols “OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN” reflect the variety of methods APDN lists their stock as, and were valid at the time of original publication of this press release.
(PublicWire.com News Release) Applied DNA Sciences, Inc. (OTCQB:APDN), announces new customers and inquiries within the governments and the banking and insurance industries.
Applied DNA provides DNA markers to protect cash and valuables in transit (CViT), to protectbrand owners, and to secure legitimate supply chains against the diversion to gray markets and against the infiltration of counterfeit products. The company’s approach to each vertical market has been to sell its unique, uncopyable DNA tags to suppliers whose components enter at the bottom or through multiple points within a supply chain, and then license the platform to “pain
points” that experience the most liability.
Licensing Model Similar to Software Industry
For example, within the cash transportation industry, APDN sells its DNA markers to the security ink users, ATM cassette manufacturers, and cash box manufacturers, who supply their DNA-enhanced products to security companies and ATM owners. However, the security value in the event of theft can only be realized if the risk-owner has licensed the platform from APDN.
License Unlocks the DNA Sequence Key
“Our model is similar to that employed by the software industry,” said Dr. James Hayward, CEO of APDN. “We ensure widespread deployment of our DNA marks within an industry, in the same manner as software developers distribute software via laptops and device manufacturers. Our licensees can only realize the value of the DNA markers, just as software must be licensed to enjoy its value.” He continued: “Our DNA sequence content is only available to our licensees.
We maintain control of our sequences, and only we can authenticate the cash stolen and provide forensic support in an act perpetrated against a risk-owner, which is initially the cash-intransit transporter, but ultimately includes the financial institution and their insurer.”
APDN now has a proven track record within the CViT industry. With over 22 convictions to its credit, APDN has a 100% conviction record for captured criminals who have stolen cash from its security licensees within the UK. The result, the deterrence provided by APDN, yielded a significant drop in attacks and eliminated cash losses more than one hundred times the cost of annual licensing.
Proven Return on Investment
This proven ROI has brought APDN customers higher up the risk chain. “Banks, insurers and governments are now recognizing the deterrence that can only be provided by DNA markers,” said Dr. Hayward. “We have received initial orders from governments and insurers, and we are fielding inquiries from banks internationally. The increased demand contributed to the closing of the best quarter in our company’s history, announced in SEC filings that describe our first FY11 quarter, ending December 2010.”
About APDN
APDN sells patented DNA security solutions that provide anti-counterfeit protection, as well as protecting brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used for product authentication in a unique manner that essentially cannot be copied. When used in conjunction with other law enforcement technologies, SigNature DNA can provide a forensic chain of evidence that has been used successfully in more than 22 convictions. To learn more, go to www.adnas.com where APDN routinely posts all press releases.
The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to ur short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K, filed on December 15, 2010 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.
SOURCE Applied DNA Sciences, Inc.
INVESTOR CONTACT: Debbie Bailey, 631-444-8090, fax: 631-444-8848
MEDIA CONTACT: Janice Meraglia, 631-444-6293, fax: 631-444-8848
FCMN Contact: info@adnas.com
Web site: http://www.adnas.com
Trading Symbols
Applied DNA Sciences trades Over The Counter As APDN (OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN)
About PublicWire.com
PublicWire.com is a Small Cap Financial Press Release Company that uses a variety of cutting edge methods to syndicate your Small Cap Press Release to various news and information outlets. Our press releases have consitantly placed the Small Cap Companies we work with on the first result page of major search engines such as Google, Bing, and Yahoo. We work exclusively with Pinksheet and Over The Counter (PK and OTCBB) Companies to ensure maximum exposure for their Press Releases.
To maximize your OTCBB / Pinksheet / Small Cap Company Press Release, call us directly at 407-218-7446.
OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN
The symbols “OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN” reflect the variety of methods APDN lists their stock as, and were valid at the time of original publication of this press release.
SinoFresh Nasal Spray (SFSH.PK) Achieves Positive Results Against H1N1 (Swine Flu) Virus in Initial Pilot Animal Study
Posted on 24. Nov, 2009 by PublicWire in Medical
24 November 2009 (PublicWire) — SinoFresh HealthCare, Inc. (PINKSHEETS: SFSH) announced today the successful results of its initial pilot animal study testing the efficacy of the SinoFresh Nasal Spray product when used on animals infected with the H1N1 (”swine flu”) virus. The study data suggests that treatment with SinoFresh allowed the infected animals to recover more rapidly from H1N1 infection than did untreated animals. In addition, pre-treatment with SinoFresh Nasal Spray decreased the severity and/or incidence of infection.
Dr. Michael Stampar, D.O., Senior Medical Advisor to SinoFresh HealthCare Products, stated, “We are very encouraged by this initial study report and will continue to develop data to support our belief that SinoFresh Nasal Spray, a broad-based antiseptic solution, is an important component in protecting the health of patients that are exposed to the H1N1 (’swine flu’) virus.”
The study, which was conducted by SRS International Corp. of Falls Church, VA, was conducted over 14 days and was designed to evaluate the severity of infection from H1N1 (”swine flu”) virus in the Cotton Rat animal model, a well accepted model for studying human nasal and respiratory tract infection by viruses and other microbial pathogens. In this study, the test animals were inoculated with H1N1 and then received SinoFresh Nasal Spray in the nose three times daily for 14 days.
The study evaluated the product’s likelihood of efficacy in both prevention and treatment. One group of animals was treated with SinoFresh Nasal Spray prior to inoculation with H1N1 and a second group was treated starting 15 minutes after inoculation with H1N1 while the remaining “control group” received no treatment during the overall 14-day study period.
The Company has now also initiated a study to evaluate the product’s ability to reduce or eliminate viral shedding which is the main method of transmission of the H1N1 flu virus. The active phase of the additional study has been completed and is in the laboratory for evaluation. Results are expected in the next few weeks.
About SinoFresh(TM) HealthCare, Inc.
SinoFresh(TM) HealthCare, Inc. is a developer and marketer of therapies to treat inflammatory and infectious diseases of the upper respiratory system. The Company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms suspected of causing pathogenesis of the mouth nose and throat. The Company holds certain patents and patent applications on its innovative pharmaceutical technology and relies upon a panel of medical experts and management team experienced in the bio-pharmaceutical industry.
The Company’s product, SinoFresh(TM) Nasal & Sinus Care, is the only over-the-counter antiseptic nasal spray that kills bacteria and fungi and viral pathogens in the throat and nasal passages. The Company is also researching how antiseptic cleansing may aid in alleviating sinus distress, a problem that affects many Americans annually. More information is available at www.sinofresh.com.
*SinoFresh(TM) is a trademark of SinoFresh HealthCare, Inc.
For further information company can be contacted at 888-460-4774, or on the web at www.sinofreshproducts.com, or by email at customerservice@sinofreshproducts.com.
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements speak only as of the date on which such statements are made and involve risks and uncertainties detailed in the Company’s filings with the Securities and Exchange commission, including risks summarized in the company’s annual Report of form 10-KSB for its fiscal year ended December 31, 2006 (file No.49764). The Company’s actual results could differ materially from such forward-looking statements. The Company undertakes no obligation to update any forward-looking statement or statements to reflect new events or circumstances or future developments.
Contact:
SinoFresh
888-460-4774
www.sinofreshproducts.com
customerservice@sinofreshproducts.com
InfuSystem Holdings (INHI.OB) to Present at Lazard Capital Markets Healthcare Conference
Posted on 12. Nov, 2009 by PublicWire in Medical
12 November 2009 (Public Wire) –InfuSystem Holdings, Inc. (OTCBB: INHI); (OTCBB: INHIW); (OTCBB: INHIU), the leading provider of ambulatory infusion pumps and associated clinical services, today announced that it will participate in Lazard Capital Markets 6th Annual Healthcare Conference, to be held November 17-18, 2009, in New York. Sean McDevitt, Chairman and Chief Executive Officer of InfuSystem, is scheduled to present on Wednesday, November 18, at 1:45 PM Eastern time at the conference.
About InfuSystem Holdings, Inc.
InfuSystem is the leading supplier of infusion services to oncologists and other outpatient treatment settings. The Company provides pole mounted and ambulatory pumps, supplies and related clinical, biomedical and billing services to practices and patients, nationwide. The Company’s unique suite of services appeals to practices, patients and payors by improving access to clinically necessary medical equipment, while driving down costs and maximizing clinical outcomes.
CONTACT:
Asher Dewhurst
Bob East
Westwicke Partners
(443) 213-0500
HemaCare Reports Eighth Consecutive Profitable Quarter
Posted on 09. Nov, 2009 by PublicWire in Medical
9 November 2009 (PublicWire) — HemaCare Corporation (OTCBB: HEMA) announced today third quarter 2009 results, which include a 168% increase in income from operations compared to the same quarter of 2008. Income from operations was $158,000 versus $59,000 for the third quarter of 2008, and $659,000 on a year-to-date basis, compared to $422,000 in 2008. Net income in the quarter was $233,000, or $0.02 per share, compared to $285,000, or $0.03 per share, in the third quarter of 2008; however, the prior year period included a non-recurring gain of $396,000 related to litigation settlement.
Gross profit from continuing operations decreased $58,000, or 4%, in the quarter to $1.5 million, primarily driven by an 11% decrease in revenue compared to prior year, attributable to a 17% decrease in blood products revenue. This was the result of increased competition caused by an unprecedented excess supply of blood products in the United States due to the recent downturn in the economy. Gross profit margin from continuing operations in the quarter was 17%, compared to 16% in the third quarter of 2008.
Commenting on the results, John Doumitt, the Company’s Chief Executive Officer, stated, “While this was a challenging revenue quarter for the Company, we are pleased to have maintained profitability and are gratified that we were able to recently add new customers who recognize the important value we provide.”
Contact:
HemaCare Corporation
Robert S. Chilton
Executive Vice President and Chief Financial Officer
877-310-0717
www.hemacare.com
Bio-Path Holdings, Inc. Operations Update
Posted on 03. Nov, 2009 by PublicWire in Medical
HOUSTON–(Public Wire)– Bio-Path Holdings, Inc. (OTC BB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, issued a news release today in which the Company provided an update of drug development operations.
Previously in June of 2009, Bio-Path Holdings, Inc. issued a press release in which drug development operations and the status of commencing a Phase I clinical trial in the Company`s lead drug candidate were discussed. In that update, the Company indicated that the next major milestones were successful manufacturing of the clinical drug batch to be used in the Phase I trial, and submission of all drug manufacturing and testing data to the U.S. Food and Drug Administration (FDA). The Company confirms today that its suppliers have successfully manufactured the clinical drug batch, and that all release testing required for this drug has been completed. As a result, Bio-Path Holdings, Inc. in October submitted the necessary drug batch manufacturing and testing data to the FDA. Assuming FDA reviewers have no additional requests for information, the Company expects within 30 days that the Investigational New Drug (IND) application for its lead drug candidate will be released. Bio-Path Holdings, Inc. would then be able to commence its Phase I clinical trial.
About Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. is developing leading-edge, patented, liposomal drug delivery systems developed at The University of Texas M. D. Anderson Cancer Center, with two clinical cancer drug candidates ready for the clinic, and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path`s drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded (siRNA) and single stranded (antisense) nucleic acid compounds, with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized.
Bio-Path Holdings, Inc. will also be developing liposome tumor targeting
technology, representing next-generation enhancements to the Company`s core
liposome delivery technology.
Bio-Path Holdings, Inc.
Internal Public Relations:
Douglas P. Morris, VP Corporate Development
801-580-2326